In conclusion, our study suggests that combining anlotinib and anti‐PD‐1 immunotherapy represents a promising therapeutic strategy for advanced HCC patients, providing a theoretical basis and preclinical data to support future clinical trials. Here, PDCD1 is linked to hepatocellular carcinoma.